Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115428) titled 'BubR1 Orchestrates Insulin Receptor Endocytosis to Promote Cutaneous Squamous Cell Carcinogenesis' on Dec. 25, 2025.
Study Type: Observational study
Study Design:
Cross-sectional
Primary Sponsor: The Fourth Hospital of Changsha (Integrated Traditional Chinese and Western Medicine Hospital of Changsha)
Condition:
Cutaneous squamous cell carcinoma (cSCC)
Intervention:
adjacent tissue:None
Recruitment Status: Not Recruiting
Phase: 0
Date of First Enrollment: 2026-01-01
Target Sample Size: adjacent tissue:6;cancer tissue:6;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn...